Key result
Short-course digoxin in ADHF is linked to ~21% lower 30-day death and readmission.
Why the study?
Despite critical voices regarding its efficacy and safety, digoxin may still have a role in managing acute decompensated heart failure, warranting evaluation of short course therapy started in the emergency department.
Does short course digoxin therapy reduce all-cause mortality and HF readmission in patients with acute decompensated heart failure?
Case-Control (n=333)
Does short course digoxin therapy reduce all-cause mortality and HF readmission in patients with acute decompensated heart failure?
Odds Ratio: 0.79 (95% CI 0.71–0.89)
In patients with acute decompensated heart failure, a short course of digoxin started in the emergency department was associated with reduced 30-day mortality and readmission, as well as improved cardiac output and LVEF.
Digoxin use was associated with lower 30-day mortality and readmission in ADHF; hypothesis-generating and requires randomized confirmation before practice change.
BackgroundDespite many critical voices regarding its efficacy and safety, digoxin may still have a role in the management of heart failure.The objective of this study was to evaluate the efficacy and safety of a short course digoxin therapy started in the emergency department based on clinical outcome after 30 days post hospital discharge.Methods From Great Tunisian registry, acute decompensated heart failure (ADHF) patients from January 2016 to January 2018 were identified.Patients with incomplete data were excluded.Digoxin treated and non-treated patients were compared in a matched control study with respect to primary outcomes of all-cause mortality and HF readmission.Secondary outcomes included changes of cardiac output (CO) and left ventricular ejection fraction (LVEF) after 72 hours of hospital admission. ResultsThe study population comprised 104 digoxin treated and 229 matched non-treated with a median age of 67.4±12.8.After 72 hours of ED admission, there was a larger increase of CO (17.8 % vs 14%; p=0.015) and LVEF (14.4% vs 3.5%; p=0.003) in digoxin group compared to control group.At 30-day post-hospital discharge 34 (10.2%)patients died and 72 (21.6%) patients were readmitted.Use of digoxin was associated with decreased risk of death and hospital readmission [odds ratio, 0.79 (95% CI, 0.71-0.89)]. ConclusionIn ADHF patients, treatment with digoxin was associated with a significant decrease risk of 30-day mortality and hospital readmission with an improvement of cardiac output and left ventricular ejection fraction.
No takes yet. Share an insight, caveat, or question.
Semir Nouira (2022) conducted a case-control in Acute decompensated heart failure (ADHF) (n=333). Short course digoxin therapy vs. Matched non-treated control was evaluated on All-cause mortality and HF readmission at 30-day post-hospital discharge (OR 0.79, 95% CI 0.71-0.89). Short course digoxin therapy in acute decompensated heart failure was associated with a decreased risk of 30-day death and hospital readmission (OR 0.79; 95% CI 0.71-0.89).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: